Invex Therapeutics

Invex operates in the biopharmaceutical industry, seeking to develop efficacious treatments for neurological conditions resulting from raised intracranial pressure (ICP). ICP is a serious issue in a range of neurological conditions, including idiopathic intracranial hypertension, traumatic brain injury or acute stroke.

The company listed on the ASX in July 2019.

Contact Details

Level 1, 38 Rowland Street , SUBIACO WA 6008

08 6382 0137

info@invextherapeutics.com

www.invextherapeutics.com

Lists and Charts

Share price

Invex Therapeutics
Closing price for the last 90 trading days

View ASX Chart

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
1724^th	Dateline Resources Limited	-72%	-42.09%
1725^th	Prodigy Gold	-72%	-49.35%
1726^th	Invex Therapeutics	-72.09%	-38.48%
1727^th	Adherium	-72.34%	-53.17%
1728^th	Top Shelf International Holdings	-72.43%	0%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Revenue

Rank	Company	#
160^th	Invex Therapeutics	$1.21m
187^th	4DS Memory	$8.05k
188^th	AssetOwl	$0
189^th	Oakajee Corporation	$0
190^th	Protean Energy	$0

184 public companies - industrial WA ranked by total revenue

View Full List

Company Share Transactions

Company Activity

	NEW ROLE: David Wheeler, Non-Executive Director	31 Jul 2024
	NEW ROLE: Carol Parish,	04 Sep 2023
	REMUNERATION UPDATE: Narelle Warren, Chief Financial Officer, Company Secretary	02 Nov 2020
	NEW ROLE: Tom Duthy, Executive Director	10 Oct 2020

Related Information

Access to our data for Invex Therapeutics is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Invex Therapeutics is included in 1 list - Public Companies - Industrial WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today